TEST AND PRICE LIST FOR NEXT GENERATION SEQUENCING

Next-generation sequencing can replace Sanger sequencing in clinical diagnostics.

Next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Birgit Sikkema-Raddatz Department of Genetics, University Medical Center Groningen The Netherlands Groningen GRONINGEN

La diagnostica molecolare nelle neoplasie colo-rettali. A do Scarpa. U iversita di Vero a

La diagnostica molecolare nelle neoplasie colo-rettali C-NET A do Scarpa e Dipartime to Pato ogia e U iversita di Vero a La stessa malattia puo avere diverse patogenesi cucchiaio moneta forchetta Gastrointestinal

Nuovi Scenari in Oncologia. G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012

Nuovi Scenari in Oncologia G. Zoppoli X-Files in Nutrizione Clinica e Artificiale, 08/06/2012 WHAT is cancer? «Cancer is a genetic disease of the somatic cell» [B. Vogelstein] Ten years ago Now [Cell.

HEREDITARY CANCER GENE PANEL DG 2.3.x

HEREDITARY CANCER GENE PANEL DG 2.3.x Gene Median % covered % covered Associated Phenotype description and OMIM ID coverage >10x >20x ALK 99,5 100% 98% {Neuroblastoma, susceptibility to, 3}, 613014 APC

CancerTREATMENT NGS+ NSCLC Summary Report Page 1 of 7 PATIENT SPECIMEN PHYSICIAN

Page 1 of 7 POSITIVE TEST RESULTS Biomarker Result DETECTED NEGATIVE TEST RESULTS FDA Approved Therapies Targeting Molecular Pathway TEST DESCRIPTION: CancerTREATMENT NGS+ uses Next Generation Sequencing

Launching a Cancer Genetic Laboratory to Enhance Diagnosis and Treatment

Launching a Cancer Genetic Laboratory to Enhance Diagnosis and Treatment Arthur L. Beaudet, M.D. Department of Molecular and Human Genetics Baylor College of Medicine ORIGIN AND PRECEDENT Decades of experience

Médecine de précision médecine personnalisée en Oncologie. Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN

Médecine de précision médecine personnalisée en Oncologie Fabien Calvo, Directeur Recherche et Innovation, INCa, Directeur ITMO Cancer, AVIESAN Successful targeted drug development Rapid identification

1199 SEIU Benefit Funds Laboratory Management Program PRIOR AUTHORIZATION CODE LIST FOR OUTPATIENT MOLECULAR AND GENOMIC LABORATORY TESTS

1199 SEIU Benefit Funds Laboratory Management Program PRIOR AUTHORIZATION CODE LIST FOR OUTPATIENT MOLECULAR AND GENOMIC LABORATORY TESTS Effective January 1, 2016 Administered by evicore healthcare Refer

Test Information Sheet

Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: High/Moderate Risk Panel Sequence

Hereditary Breast Cancer Panels. High Risk Hereditary Breast Cancer Panel Hereditary Breast/Ovarian/Endometrial Cancer Panel

P A T I E N T G U I D E Hereditary Breast Cancer Panels High Risk Hereditary Breast Cancer Panel Hereditary Breast/Ovarian/Endometrial Cancer Panel B a y l o r M i r a c a G e n e t i c s L a b o r a t

Section: Genetic Testing Last Reviewed Date: October 2015. Policy No: 73 Effective Date: November 1, 2015

Medical Policy Manual Topic: Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Date of Origin: July 2014 Section: Genetic Testing Last Reviewed Date: October 2015 Policy No: 73 Effective

NEIGE. diagnosis In oncogenetics. Nicolas Sévenet 02 juillet 2012. n.sevenet@bordeaux.unicancer.fr

NEIGE g for molecular NExt g generation sequencing diagnosis In oncogenetics Nicolas Sévenet 02 juillet 2012 n.sevenet@bordeaux.unicancer.fr t@b d i f Reports 15 years Next generation sequencing 06/2011

Oncomine Cancer Panel Patient Test Report

Oncomine Cancer Panel Patient Test Report SUBJECT NFORMATON Pre-Screening Subject No.: Life Technologies Clinical Services Lab 910 Riverside Parkway, Suite 60 West Sacramento, CA 95605 Ph: (888) 734-8588

Beyond BRCA the Future is Now

Beyond BRCA the Future is Now Richard P. Frieder, MD Medical Director, Intelegene Assistant Clinical Professor Department of Obstetrics and Gynecology David Geffen School of Medicine, UCLA University of

Big Data Part I: Data-Driven Life Sciences Innovation, Personalized Medicine and Research

Big Data Part I: Data-Driven Life Sciences Innovation, Personalized Medicine and Research December 9, 2014 www.mwe.com Boston Brussels Chicago Düsseldorf Frankfurt Houston London Los Angeles Miami Milan

Test Information Sheet

Test Information Sheet GeneDx 207 Perry Parkway Gaithersburg, MD 20877 Phone: 888-729-1206 Fax: 301-710-6594 E-mail: wecare@genedx.com www.genedx.com/oncology OncoGene Dx: Breast/Ovarian Cancer Panel Sequence

A Decision Support Tool to Facilitate Cancer Risk Assessment and Referral for Genetics Services. Kristen Vogel Postula, MS, CGC & Leigh Baumgart, PhD

A Decision Support Tool to Facilitate Cancer Risk Assessment and Referral for Genetics Services Kristen Vogel Postula, MS, CGC & Leigh Baumgart, PhD Importance of Family History Increasing awareness of

Ion AmpliSeq Technology

Ion AmpliSeq Technology Dr. Franziska Freund Sr. Sequencing Sales Specialist 26.06.2015 1 The world leader in serving science Ion AmpliSeq Technology: As Simple As PCR Your targets, your genome, your panel

Ovarian Cancer Genetic Testing: Why, When, How?

Ovarian Cancer Genetic Testing: Why, When, How? Jeffrey Dungan, MD Associate Professor Division of Clinical Genetics Department of Obstetrics & Gynecology Northwestern University Feinberg School of Medicine

Cancer Genomics & Precision Medicine in the 21 st Century. Lee J. Helman, MD Scientific Director for Clinical Research CCR, NCI

Cancer Genomics & Precision Medicine in the 21 st Century Lee J. Helman, MD Scientific Director for Clinical Research CCR, NCI Outline Define terms Describe vision for how genetic characterization of tumors

Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests

Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests James H. Doroshow, M.D. NCI Deputy Director for Clinical and Translational Research NCI Workshop: Evidence Needed

Microsatellite Instability (MSI) A New Paradigm in Cancer Treatment. Lynch Syndrome OUTLINE. GI Molecular Pathology

OUTLINE GI Molecular Pathology Microsatellite Instability and Lynch Syndrome GI Cancer Genotyping KRAS Mutations in Colorectal Cancer A. John Iafrate MD-PhD Department of Pathology Massachusetts General

Approaches to Integrating Next Generation Sequencing into the Electronic Health Record

AMIA Webinar April 16, 2014 Approaches to Integrating Next Generation Sequencing into the Electronic Health Record Peter Tarczy-Hornoch, University of Washington On behalf of the Clinical Sequencing Exploratory

J Clin Oncol 32:2001-2009. 2014 by American Society of Clinical Oncology INTRODUCTION

VOLUME 32 NUMBER 19 JULY 1 2014 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment Allison W. Kurian,

High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma

High-Throughput Mutation Profiling Identifies Frequent Somatic Mutations in Advanced Gastric Adenocarcinoma The Harvard community has made this article openly available. Please share how this access benefits

Hereditary Breast Cancer Testing. Diagnostic

Hereditary Cancer Testing Diagnostic New solutions for hereditary breast cancer. Identifying and understanding the genetic contribution to breast cancer allows for individualized disease management and

Prevalenza delle mutazioni TMEM127 nel feocromocitoma sporadico

Prevalenza delle mutazioni TMEM127 nel feocromocitoma sporadico Giuseppe Opocher Veneto Institute of Oncology and Department of Medical and Surgical Sciences, University of Padova, Italy Sympathetic paraganglia

2014 CPT Code Updates

2014 CPT Code Updates This publication is a summary of The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory effective January 1, 2014.

Genetics and Breast Cancer. Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service

Genetics and Breast Cancer Elly Lynch, Senior Genetic Counsellor Manager, Austin Health Clinical Genetics Service Overview Background/Our Team What is the difference between sporadic/familial cancer? How

The Genetics of Early- Onset Breast Cancer. Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine

The Genetics of Early- Onset Breast Cancer Cecelia Bellcross, Ph.D., M.S.,C.G.C. Department of Human Genetics Emory University School of Medicine All cancers are genetic BUT Not all cancers are hereditary

Target enrichment using selector probes. Department of Genetics and Pathology, Uppsala University

Target enrichment using selector probes Mats Nilsson Department of Genetics and Pathology, Uppsala University Target enrichment using selector probes Even with radically improved sequencing throughput,

PATOLOGIA MOLECULAR DEL CANCER GINECOLOGICO. Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA.

PATOLOGIA MOLECULAR DEL CANCER GINECOLOGICO Xavier Matias-Guiu Hospital Universitari Arnau de Vilanova, Universitat de Lleida, IRBLLEIDA. Carcinoma de Endometrio Cáncer de Ovario Endometrial carcinoma

Breast and Ovarian Cancer

Breast and Ovarian Cancer Hereditary Breast and Ovarian Cancer A Guide for Clinicians KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS Hereditary Breast and Ovarian Cancer Panel

Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics

EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC

Molecular Human Genetics. Cancer, Tumor suppressor genes, Oncogenes

Youtube ARCC http://www.youtube.com/watch?v=3pobqrfz0no It's Our Time - American Association for Cancer Research (AACR) Molecular Human Genetics Cancer, Tumor suppressor genes, Oncogenes Hum 2014/15 1

6/10/2015. Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond. Hereditary Cancers. BRCA1 and BRCA2 Review

Hereditary Predisposition for Breast Cancer: Looking at BRCA1/BRCA2 Testing & Beyond Arturo Anguiano MD, FACMG International Medical Director, Medical Affairs Vice Chairman, Genetics; Medical Director,

How To Write A Cancer Sequencing

Evalua&ng tumor exome sequencing in the oncology clinic: Lessons from the BASIC3 study GBM Cancer Risk? A Clinical Sequencing Exploratory Research (CSER) project Supported by NHGRI/NCI 1U01HG006485 ISMB2014

Genomic instability in cancers and cancer predispositions. Popova Tatiana Inserm U830 Institut Curie

Genomic instability in cancers and cancer predispositions Popova Tatiana Inserm U830 Institut Curie Time-scale in a tumor genome discovery Bovery HYP Cancer genome Knudson 2 hit HYP Tumor DNA has transforming

Colon Cancer Syndromes. Robin B. Mendelsohn MD Memorial Sloan Kettering Cancer Center Department of Medicine Gastroenterology and Nutrition Service

Colon Cancer Syndromes Robin B. Mendelsohn MD Memorial Sloan Kettering Cancer Center Department of Medicine Gastroenterology and Nutrition Service Background: Etiology of Colorectal Cancer (CRC) Sporadic:

Cardio Gene panel experience. Jan Jongbloed Laboratory Specialist Clinical Genetics Genome Diagnostics Department of Genetics UMCG Groningen

Cardio Gene panel experience Jan Jongbloed Laboratory Specialist Clinical Genetics Genome Diagnostics UMCG Groningen CardioGenetics: Rowida Almomani Ludolf Boven Anne Herkert Yvonne Hoedemaekers Irene

Common Cancers & Hereditary Syndromes

Common Cancers & Hereditary Syndromes Elizabeth Hoodfar, MS, LCGC Regional Cancer Genetics Coordinator Kaiser Permanente Northern California Detect clinical characteristics of hereditary cancer syndromes.

Submitted 12 September 2014; accepted 12 September 2014; advance online publication 13 November 2014. doi:10.1038/gim.2014.147. Genetics in medicine

American College of Medical Genetics and Genomics ACMG Practice Guidelines A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors:

Progress and Prospects in Ovarian Cancer Screening and Prevention

Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian

WHITE PAPER SEPT 2015

WHITE PAPER SEPT 2015 LIQUID BIOPSY FOR THE DETECTION AND MONITORING OF CANCER: ANALYSIS OF 96 HOTSPOT MUTATIONS VIA PLASMA DERIVED CIRCULATING TUMOR DNA PATHWAY GENOMICS CANCER AND SOMATIC MUTATIONS The

Molecular Pathology/Molecular Diagnostics/Genetic Testing

Policy Number GEN01252012RP Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 01/28/2015 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable

July 14, 2014. Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244

ASCP s Statements before the Centers for Medicare and Medicaid Services Regarding Recommendations for Crosswalking/Gapfilling New CPT s for the CLFS for CY 2015 and the Revaluation of the Clinical Laboratory

Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment

Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment Policy #: 133 Latest Review Date: April 2015 Category: Laboratory Policy Grade: D

Next Generation Sequencing in Early-Phase Clinical Trials in Cancer Filip Janku

11 th International Congress on Targeted Anticancer Therapies Paris March 4-6, 2013 Next Generation Sequencing in Early-Phase Clinical Trials in Cancer Filip Janku Investigational Cancer Therapeutics (Phase

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes

PRACTICE GUIDELINES nature publishing group 223 CME ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes Sapna Sy nga l, MD, M PH, FAC G 1, 2, 3, R and

Towards new classifications and individualised treatment for cancer patients

Towards new classifications and individualised treatment for cancer patients Professor Thomas TURSZ General Director Institut Gustave Roussy Villejuif Paris - France Workshop Chemores Milano January 21

Metastatic Hereditary Breast Cancer: What s New? Melinda Telli, M.D. Assistant Professor of Medicine Stanford University School of Medicine

Metastatic Hereditary Breast Cancer: What s New? Melinda Telli, M.D. Assistant Professor of Medicine Stanford University School of Medicine Outline Treatment principles in metastatic breast cancer Update

Clinical Use of Molecular Diagnos@cs in the Treatment of Lung Cancer

Clinical Use of Molecular Diagnos@cs in the Treatment of Lung Cancer Tianhong Tina Li, MD, PhD (thli@ucdavis.edu) Associate Professor of Clinical Medicine, School of Medicine Disclosures Grants/Research

CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE

CANCER RESEARCH UK STRATIFIED MEDICINE PROGRAMME IAN WALKER PHD, MBA HEAD OF STRATIFIED MEDICINE Agenda Introduction to Cancer Research UK CRUK Stratified Medicine Programme Key Challenges and Lessons

Molecular pathology of thyroid cancers

Molecular pathology of thyroid cancers Peter Lakatos 1st Department of Medicine Semmelweis University Thyroid nodules 4-7% of population with palpable nodules More frequent in women Incidence increasing

Disclosures. Personalized Meds from the molecular onco-pathology s perspective

1 FIGON DMD Symposium From Protocol towards Personalized Tailored Therapy Ede, October 6th 2015 Personalized Meds from the molecular onco-pathology s perspective Diagnostic in Pathology in 2015-2020 Molecular

Immunophenotyping of hereditary breast cancer

Immunophenotyping of hereditary breast cancer Petra van der Groep Cover design: P. van der Groep Lay-out: Gildeprint Drukkerijen - Enschede, The Netherlands Printed by: Gildeprint Drukkerijen - Enschede,

Application of Molecular Diagnosis: Present and Future

Application of Molecular Diagnosis: Present and Future Dong Jun Lim, MD., PhD. Associate Professor Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary s Hospital,

The Future of Clinical Chemistry and Laboratory Medicine, The Diagnostics Industry View

The Future of Clinical Chemistry and Laboratory Medicine, The Diagnostics Industry View Peng Yin, M.D., Ph.D., Director, Global Scientific Affairs Abbott Diagnostic Division (ADD) Agenda Lack of perceived

Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment

Name of Policy: Genetic Testing for Inherited Cancer Predisposition and/or Pharmacogenetics related to Cancer Treatment Policy #: 133 Latest Review Date: April 2015 Category: Laboratory Policy Grade: D

UW Carbone Cancer Center Precision Medicine Molecular Tumor Board V3. 12.18.15 Page 1

The UW Carbone Cancer Center Precision Medicine Molecular Tumor Board In partnership with the UW Collaborative Genomics Core, the UW Carbone Cancer Center (UWCCC) has developed a Precision Medicine Molecular

Stato dell arte e prospettive delle terapie a bersaglio molecolare nel carcinoma polmonare

Stato dell arte e prospettive delle terapie a bersaglio molecolare nel carcinoma polmonare Giorgio V. Scagliotti Università di Torino Dipartimento di scienze cliniche & biologiche giorgio.scagliotti@unito.it

Een behandeling op maat voor iedere patient: wat betekent dat in de praktijk? Emile Voest

Een behandeling op maat voor iedere patient: wat betekent dat in de praktijk? Emile Voest Need for personalised cancer treatment Scenario: patient with metastasized colorectal cancer Doctor suggests treatment

Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes. Dr. med. Henrik Csaba Horváth

Risk stratification for colorectal cancer especially: the difference between sporadic disease and polyposis syndromes Dr. med. Henrik Csaba Horváth Why is risk stratification for colorectal cancer (CRC)

Genomic Clinical Trials: NCI Initiatives

Genomic Clinical Trials: NCI Initiatives James H. Doroshow, M.D. Deputy Director for Clinical and Translational Research National Cancer Institute National Cancer Advisory Board Washington, DC December

European Biotechnology. News. II Genomic Therapies and & Diagnostics SPECIAL. Science & Industry. April 2013

April 2013 European Biotechnology Science & Industry News II Genomic Therapies and & Diagnostics SPECIAL European Biotechnology Network Join the European Biotechnology Network! The European Biotechnology

Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry

The American Journal of Surgery (2013) 205, 608-612 North Pacific Surgical Association Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer

Molecular Stratification of Cancer in the

Molecular Stratification of Cancer in the Clinical Setting David Gonzalez de Castro Molecular Diagnostics NHS FT and The Institute of Cancer Research, London, UK 1 2 The complexity of human cancer genomes

Number 12.04.115 Effective Date December 8, 2015 Revision Date(s) 12/08/15; 06/09/15; 02/10/15; 10/13/14; 05/12/14 Replaces 2.04.

MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Expanded Molecular Panel Testing of Cancers to Identify Targeted

National Medical Policy

National Medical Policy Subject: Policy Number: Genetic Testing for BRCA1 and BRCA2 NMP136 Effective Date*: April 2004 Updated: September 2015 This National Medical Policy is subject to the terms in the

Essais de médicine personnalisée en cancérologie. Jean-Charles SORIA

Essais de médicine personnalisée en cancérologie Jean-Charles SORIA Cured Cancer patients 2.8 M / year in the EU Local failure Not cured Distant failure Cured Cancer patients 2.8 M / year in the EU Not

Pancreatic Cancer. Hereditary Pancreatic Cancer A Guide for Clinicians KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS

Pancreatic Cancer Hereditary Pancreatic Cancer A Guide for Clinicians KNOWING WHAT TO LOOK FOR KNOWING WHERE TO LOOK AND KNOWING WHAT IT MEANS Hereditary Pancreatic Cancer Panel Advances in molecular genetics

Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities

Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities Vincent A. Miller, M.D. Foundation Medicine, Inc. AACR Annual Meeting 2012 Current Concepts session

User Guide Thank you for purchasing the DX90 http://www.ibasso.com

Riesgo genético y familiar. Javier Benitez Centro Nacional Investigaciones Oncológicas Madrid

Riesgo genético y familiar Javier Benitez Centro Nacional Investigaciones Oncológicas Madrid Cancer: An example of complex disease 80-85% of cancers Polygenic model (combination of X genes) Low penetrance

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But

The Fanconi anaemia/brca pathway and cancer susceptibility. Searching for new therapeutic targets

Clin Transl Oncol (2008) 10:78-84 DO 10.1007/s12094-008-0160-6 EDUCATONAL SERES Green Series* The Fanconi anaemia/brca pathway and cancer susceptibility. Searching for new therapeutic targets M.ª José

Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers

RESEARCH ARTICLE Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers Nicky D Haene 1, Marie Le Mercier 1, Nancy De Nève 1, Oriane Blanchard 1, Mélanie Delaunoy 2, Hakim

Recommendations for the management of early breast cancer

Recommendations for the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk of a gene mutation FEBRUARY 2014 Incorporates published evidence to August

Molecular Diagnosis of Gastrointestinal Tumors

Molecular Diagnosis of Gastrointestinal Tumors Zoltan Szentirmay National Institute of Oncology Center of Surgical and Molecular Tumor Pathology EEA and Norwegian Financial Mechanisms in Hungary, Development

Genomic Medicine Education Initiatives of the College of American Pathologists

Genomic Medicine Education Initiatives of the College of American Pathologists Debra G.B. Leonard, MD, PhD, FCAP Chair, Personalized Healthcare Committee, CAP Professor of Pathology, Weill Cornell Medical

MRC-Holland MLPA. Related SALSA MLPA probemixes P417 BAP1: Contains probes for each exon of BAP1 gene on 3p21.

SALSA MLPA probemix P027-C1 Uveal melanoma Lot C1-0814 & C1-0213 & C1-0211: A large number of probes have been replaced by other probes in the same chromosomal regions as compared to previous lots, and

Oncogeni: fattori di crescita

Oncogeni: fattori di crescita Oncogeni: recettori per fattori di crescita Oncogeni: trasduttori del segnale Oncogeni: fattori trascrizionali Meccanismo di azione degli oncogeni 2 recettore 2 per il fattore

Oncology Insights Enabled by Knowledge Base-Guided Panel Design and the Seamless Workflow of the GeneReader NGS System

White Paper Oncology Insights Enabled by Knowledge Base-Guided Panel Design and the Seamless Workflow of the GeneReader NGS System Abstract: This paper describes QIAGEN s philosophy and process for developing

***Next Generation sequencing testing options available effective April 18 th, 2016***

***Next Generation sequencing testing options available effective April 18 th, 2016*** Genetic Test Next Generation Sequencing NF1-RASopathy Panel Testing NF1-only NGS testing and copy number analysis

***Next Generation sequencing testing options available effective April 18 th, 2016***

***Next Generation sequencing testing options available effective April 18 th, 2016*** Genetic Test Next Generation Sequencing NF1-RASopathy Panel Testing NF1-only NGS testing and copy number analysis

Genomic Analysis of Mature B-cell Malignancies

Genomic Analysis of Mature B-cell Malignancies Update and Lessons Learned Omar Abdel-Wahab, MD Memorial Sloan Kettering Cancer Center Human Oncology and Pathogenesis Program and Leukemia Service Disclaimer:

Can molecular targeted therapies win the war against cancer?

Can molecular targeted therapies win the war against cancer? DR. PETÁK ISTVÁN PHD KPS MOLEKULÁRIS DIAGNOSZTIKAI KÖZPONT MTA-SE PATHOBIOKÉMIAI MUNKACSOPORT Anti- GEFITINIB An - M+ KRAS Schwab Richárd, Peták

THE LEADING EDGE FALL 2015 ISSUE. Welcome... 1. ICD-10 is Here for Pathology... 2. 2016 CLFS for Drugs of Abuse Testing... 5

FALL 2015 ISSUE Welcome... 1 ICD-10 is Here for Pathology... 2 2016 CLFS for Drugs of Abuse Testing... 5 Common Causes of Enrollment Delays... 10 ICD-10 is Here!... 12 High Deductible Plans Grow Despite

GENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110

GENETIC TESTING FOR INHERITED MUTATIONS OR SUSCEPTIBILITY TO CANCER OR OTHER CONDITIONS MED207.110 COVERAGE: Pre- and post-genetic test counseling may be eligible for coverage in addition to the genetic

MEDICAL POLICY Genetic Testing

POLICY.........PG0041 EFFECTIVE......01/01/12 LAST REVIEW... 04/22/16 MEDICAL POLICY Genetic Testing GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by

Genetic Testing for Familial Adenomatous Polyposis and MYH-Associated Polyposis (Lynch Syndrome)

Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance

Molecular Diagnosis of Follicular Cell Nodules

Endocrine Pathology Society Companion Meeting USCAP 2015 Molecular Diagnosis of Follicular Cell Nodules Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical

2 nd PROCART Forum. October 9th, 2012

2 nd PROCART Forum October 9th, 2012 The main investments in cancer research 2012 research Spending 120 M Including INCa, Aviesan cancer, Ministry of Health cancer biology, cancer sciences, genomics Activities

PATH-SCAN: A REPORTING TOOL FOR IDENTIFYING CLINICALLY ACTIONABLE VARIANTS

PATH-SCAN: A REPORTING TOOL FOR IDENTIFYING CLINICALLY ACTIONABLE VARIANTS ROXANA DANESHJOU 1, ZACHARY ZAPPALA 1, KIM KUKURBA 1, SEAN M BOYLE 1, KELLY E ORMOND 1, TERI E KLEIN 1, MICHAEL SNYDER 1, CARLOS

targeted cancer therapy

LUNG CANCER TREATMENTS What you need to know about... targeted cancer therapy foreword About LUNGevity LUNGevity is the largest national lung cancer-focused nonprofit, changing outcomes for people with

Population-based family studies: Genetic contribution to cancer development and survival?

Department of Medical Epidemiology and Biostatistics Karolinska Institutet, Stockholm, Sweden Population-based family studies: Genetic contribution to cancer development and survival? Linda Sofie Lindström

Laboratory User Guides

CLINICAL GENETIC SERVICE Laboratory User Guides (Website version) January 2016 DEPARTMENT OF HEALTH GOVERNMENT OF HONG KONG SAR Page 1 of 10 Compared with the previous version of January 2015, several

Successes and Limitations of Targeted Cancer Therapy in Lung Cancer

Successes and Limitations of Targeted Cancer Therapy in Lung Cancer Kenichi Suda a, b Tetsuya Mitsudomi a a Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama,

1. Le mutazioni di KRAS hanno tutte lo stesso significato clinico?

EGFR downstream pathways KRAS domande frequenti ed importanti. Luca Mazzucchelli Istituto cantonale di patologia Locarno )'"* )-# %& # +%,!"# '( "#$ Anti-EGFR monoclonal antibodies (MoAbs) Cetuximab and